Kitov Pharma Ltd. Banner Image

Kitov Pharma Ltd. has reached its limit for free report views

Work for Kitov Pharma Ltd.? Upgrade Your Profile and unlock all your annual reports.

Kitov Pharma Ltd.

  • Ticker KTOV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Kitov Pharma Ltd. Logo Image
  • 1-10 Employees
  • Based in Tel Aviv, Israel
Kitov Pharma Ltd. (“Kitov”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Kitov’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3More. Kitov is currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Kitov plans to advance CM24 as a combination therapy with anti-PD1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer NSCLC and pancreatic cancer.
Kitov Pharma Ltd.

Most Recent Annual Report

Kitov Pharma Ltd.
MOST RECENT 2019 Annual Report

Report Locked. Kitov Pharma Ltd. has reached its limit for free report views.

Older/Archived Annual Reports